Etokimab (I-Mab Biopharma), which is optimized for common IL-33 gene polymorphisms, has completed patient recruitment in its ...

A drug that can be taken orally could soon rival the likes of Ozempic for treating type 2 diabetes and obesity, according to ...

Leading oncology centers in the United States engaged to conduct the Phase 2 Antiviral Trial and further advance the development of PUL-042 HOUSTON, TX, UNITED STATES, July 8, 2025 /EINPresswire.com/ ...

Verona Pharma VRNA has signed a definitive agreement with pharma bigwig Merck MRK. Per the terms, the pharma giant will ...

BACKGROUND The addition of long acting inhaled β2 agonists is recommended at step 3 of the British guidelines on asthma management but a recent study suggested no additional benefit in children with ...

Acute, severe exacerbations of asthma present a challenge due to the significant morbidity associated with this presentation. For exacerbations that are refractory to initial treatments with inhaled ...

Long-acting Anticholinergic Drugs in Asthma Tiotropium is the first long-acting anticholinergic drug that has been developed in the early 1990s and approved for the management of stable COPD. [102 ...

Dupilumab use in asthma linked to higher lymphoma risk, especially T/NK cell types, though overall mortality was lower, new ...

The Business Research Company's Asthma and COPD Drugs Market 2025: Strategic Insights for Growth, Expansion, and Gaining Competitive Edge It will grow to $50.99 billion in 2029 at a compound annual ...

The Lancet on the anti-IL-5 antibody mepolizumab in individuals with allergic asthma, evidence has accumulated that the pathogenetic role of eosinophils is fundamentally different between asthma ...

COPD: Chronic obstructive pulmonary disease; EIB: Exercise-induced bronchoconstriction; IβA: Inhaled β 2-agonist; ICS: Inhaled corticosteroid. Globally, the prevalence of asthma continues to ...

White, B. H. & Cohen, J. B. Agonist-induced changes in the structure of the acetylcholine receptor M2 regions revealed by photoincorporation of an uncharged nicotinic noncompetitive antagonist.